title: Expression of lethal mutations is suppressed in neoplastically transformed cells and after treatment of normal cells with carcinogens.
abstract: Recent evidence from our laboratory suggests that the fraction of cells with lethal mutations is lost from the population by apoptosis. The relationship of this process to genetic instability and carcinogenesis is unclear. To examine this, tumorigenic cell populations derived from spontaneously occurring, neoplastically transformed C3H 1OT1/2 foci and from radiation-induced foci were compared with wild-type C3H 10T1/2 cell populations to determine the frequency of induction of lethal mutations postirradiation. Lethal mutations did not occur in the progeny of cells from type 3 foci derived from cultures of spontaneously occurring or radiation-induced neoplastically transformed cells but were very frequent in the progeny of irradiated wild-type cells. Normal human cells (HPV-immortalized human keratinocytes and primary human normal uroepithelium) were then treated with carcinogens or transfected with the Ha-ras oncogene to see if these carcinogenic events affected the yield of lethal mutations postirradiation. In each case, cells which were exposed to a carcinogenic agent had reduced numbers of lethal mutations, elevated levels of stable p53 and Bcl-2 proteins and reduced evidence of apoptosis. It is suggested that lethal mutations may represent an active safety mechanism which may deal with radiation-induced genomic instability and which is disabled early in carcinogenesis.
authors.affiliation: Dublin Institute of Technology, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: Mothersill
authors.forename: F
authors.initials: F
authors.lastname: Lyng
authors.forename: S
authors.initials: S
authors.lastname: O'Reilly
authors.forename: J
authors.initials: J
authors.lastname: Harney
authors.forename: C B
authors.initials: CB
authors.lastname: Seymour
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D002273:Carcinogens / Q000633:toxicity; D002460:Cell Line; D002461:Cell Line, Transformed; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D002999:Clone Cells; D003037:Cobalt Radioisotopes; D004305:Dose-Response Relationship, Drug; D004848:Epithelium; D005804:Genes, Lethal; D011905:Genes, ras; D006801:Humans; D015603:Keratinocytes; D051379:Mice; D008809:Mice, Inbred C3H; D016296:Mutagenesis; D009602:Nitrosamines / Q000633:toxicity; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis; D014551:Urinary Tract
chemical_list: D002273:Carcinogens; D003037:Cobalt Radioisotopes; D009602:Nitrosamines; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53